Fig. 2.
Overall survival among patients with AML-MRC. a Overall survival for all patients with AML-MRC treated with azacitidine or CCR. b Sensitivity analysis, in which patients who switched to alternate therapy were censored at the time they did so. c Overall survival by NCCN cytogenetic risk. d Overall survival by age group